Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Ritonavir is a HIV-1 and HIV-2 protease inhibitor (EC50 values are 0.022-0.13 and 0.16 μM, respectively). Blocks the metabolism of protease inhibitors by liver enzyme cytochrome P450-3A4 (CYP3A4). Orally bioavailable. When used in combination with lopinavir, improves outcome in an animal model of MERS-CoV infection.
Ritonavir is also offered as part of the Tocriscreen Antiviral Library and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||14.42||20 with gentle warming|
The following data is based on the product molecular weight 720.94. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||6.94 mL||34.68 mL||69.35 mL|
|1 mM||1.39 mL||6.94 mL||13.87 mL|
|2 mM||0.69 mL||3.47 mL||6.94 mL|
|10 mM||0.14 mL||0.69 mL||1.39 mL|
References are publications that support the biological activity of the product.
Kempf et al (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc.Natl.Acad.Sci.U.S.A. 92 2484 PMID: 7708670
Kempf et al (1998) Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J.Med.Chem. 41 602 PMID: 9484509
Zeldin et al (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J.Antimicrob.Chemother. 53 4 PMID: 14657084
Chan et al (2015) Treatment with Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J.Infect.Dis. 12 1904 PMID: 26198719
If you know of a relevant reference for Ritonavir, please let us know.
Keywords: Ritonavir, Ritonavir supplier, HIV-1, HIV-2, proteases, inhibitors, inhibits, cytochrome, P450-3A4, human, immunodeficiency, virus, orally, active, MERS-CoV, middle, east, respiratory, syndrome, coronaviruses, ABT-538, A-84538, Abbot, 84538, COVID-19, HIV, Protease, Coronavirus, 5856, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Ritonavir. Do you know of a great paper that uses Ritonavir from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Ritonavir and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.